𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A phase II trial of dexamethasone, vitamin D, and carboplatin in patients with hormone-refractory prostate cancer

✍ Scribed by Thomas W. Flaig; Albaha Barqawi; Gary Miller; Madeleine Kane; Chan Zeng; E. David Crawford; L. Michael Glodé

Publisher
John Wiley and Sons
Year
2006
Tongue
English
Weight
125 KB
Volume
107
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II trial of paclitaxel, estramusti
Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone-refractory prostate carcinoma
✍ David C. Smith; Christopher H. Chay; Rodney L. Dunn; Jude Fardig; Peg Esper; Kar 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 127 KB 👁 1 views

## Abstract ## BACKGROUND Preclinical data suggest that the combination of intravenous (i.v.) paclitaxel, carboplatin, oral etoposide, and oral estramustine (TEEC) has significant activity in patients with advanced, hormone‐refractory prostate carcinoma. The authors conducted this clinical trial t

A phase II trial of estramustine and eto
A phase II trial of estramustine and etoposide in hormone refractory prostate cancer: A Southwest Oncology Group trial (SWOG 9407)
✍ Kenneth J. Pienta; Emily I. Fisher; Mario A. Eisenberger; Glenn M. Mills; J. Wen 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB 👁 2 views

BACKGROUND. The combination of oral estramustine and oral etoposide has generated response rates of 40±50% in patients with hormone refractory prostate cancer in single institution trials. This study tested this regimen in a multi-institutional setting. METHODS. Fifty-®ve patients were accrued over

A phase 2 study of carboplatin plus doce
A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel
✍ Robert W. Ross; Tomasz M. Beer; Susanna Jacobus; Glenn J. Bubley; Mary-Ellen Tap 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 79 KB 👁 2 views

## Abstract ## BACKGROUND. Prostate cancer is the second leading cause of cancer mortality among men in the U.S. To the authors' knowledge, there is no proven, effective, second‐line therapy for docetaxel‐refractory disease. Recent data suggest that platinum salts may be effective when combined wi